Clinical Pharmacology and Therapeutics
-
Publication Venue For
- Managing Increased Accessibility to Pharmacogenomic Data.. 106:922-924. 2019
- Genetic Variants Associated With Vincristine-Induced Peripheral Neuropathy in Two Populations of Children With Acute Lymphoblastic Leukemia.. 105:1421-1428. 2019
- A Novel Method to Estimate Long-Term Chronological Changes From Fragmented Observations in Disease Progression.. 105:436-447. 2019
- Pharmacologic Targeting of Red Blood Cells to Improve Tissue Oxygenation.. 104:553-563. 2018
- Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects.. 103:778-786. 2018
- Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia.. 103:888-898. 2018
- Comparison of Outcomes Following a Switch From a Brand to an Authorized Versus Independent Generic Drug.. 103:310-317. 2018
- Harnessing the Power of Real-World Evidence (RWE): A Checklist to Ensure Regulatory-Grade Data Quality.. 103:202-205. 2018
- Emerging Therapies for Congestive Heart Failure.. 103:77-87. 2018
- Cancer Moonshot Data and Technology Team: Enabling a National Learning Healthcare System for Cancer to Unleash the Power of Data.. 101:613-615. 2017
- Improving the tools of clinical pharmacology: Goals for 2017 and beyond.. 101:22-24. 2017
- Polyallelic structural variants can provide accurate, highly informative genetic markers focused on diagnosis and therapeutic targets: Accuracy vs. Precision.. 99:169-171. 2016
- Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.. 99:36-37. 2016
- Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine.. 98:71-75. 2015
- Pharmacokinetics, Pharmacodynamics, and Safety of Lisinopril in Pediatric Kidney Transplant Patients: Implications for Starting Dose Selection.. 98:25-33. 2015
- Improving evidence developed from population-level experience with targeted agents.. 97:478-487. 2015
- Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase.. 97:326-335. 2015
- Human endotoxin administration as an experimental model in drug development.. 96:418-422. 2014
- Phenotype standardization for statin-induced myotoxicity.. 96:470-476. 2014
- The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.. 96:423-428. 2014
- Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents.. 96:429-437. 2014
- Improving the assessment of heart toxicity for all new drugs through translational regulatory science.. 95:501-508. 2014
- Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.. 95:141-146. 2014
- Integrated efficacy to effectiveness trials.. 95:131-133. 2014
- Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology.. 95:154-167. 2014
- Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy.. 94:570-573. 2013
- Pharmacometabolomics of statin response.. 94:562-565. 2013
- Purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomics-informed pharmacogenomics.. 94:525-532. 2013
- Therapeutic implications of biomarkers in chronic heart failure.. 94:468-479. 2013
- Biomarkers for smoking cessation.. 93:526-538. 2013
- A network-heuristic approach to improve the impact of genomic data on drug discovery.. 93:295-297. 2013
- Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.. 93:153-158. 2013
- Drug shortages in the United States: a critical evaluation of root causes and the need for action.. 93:133-135. 2013
- Using genetics to enable studies on the prevention of Alzheimer's disease.. 93:177-185. 2013
- The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure.. 93:57-67. 2013
- The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers.. 92:214-220. 2012
- The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.. 92:112-117. 2012
- Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine.. 91:889-895. 2012
- Impediments to clinical research in the United States.. 91:535-541. 2012
- Rational opioid dosing in the elderly: dose and dosing interval when initiating opioid therapy.. 91:339-343. 2012
- Pharmacodynamic evaluation of clopidogrel plus PA32540: the Spaced PA32540 With Clopidogrel Interaction Gauging (SPACING) study.. 90:860-866. 2011
- Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response.. 90:568-574. 2011
- The Achilles' heel of cardiovascular genetic testing: distinguishing pathogenic mutations from background genetic noise.. 90:496-499. 2011
- Practical ethics: establishing a pathway to benefit for complex pharmacogenomic tests.. 90:25-27. 2011
- Angiotensin receptor blockers and angiotensin-converting enzyme inhibitors: challenges in comparative effectiveness using Medicare data.. 89:674-682. 2011
- Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates.. 89:702-707. 2011
- Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.. 89:97-104. 2011
- Genetic variation in IL28B: impact on drug development for chronic hepatitis C infection.. 88:708-711. 2010
- Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials.. 87:668-671. 2010
- The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration.. 87:539-542. 2010
- A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.. 87:445-451. 2010
- Safety and pharmacokinetics of repeat-dose micafungin in young infants.. 87:93-99. 2010
- Clinical trial design in neonatal pharmacology: effect of center differences, with lessons from the Pediatric Oncology Cooperative Research experience.. 86:589-591. 2009
- Benefits exceed risks of newer antidepressant medications in youth--maybe.. 86:355-357. 2009
- QT as a safety biomarker in drug development.. 86:101-104. 2009
- The clinical utility index as a practical multiattribute approach to drug development decisions.. 86:105-108. 2009
- Stimulation of cholecystokinin-A receptors with Gl181771X: a failed clinical trial that did not test the pharmacogenetic hypothesis for reduction of food intake.. 85:362-365. 2009
- Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: a meta-analysis.. 84:315-319. 2008
- Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.. 84:326-331. 2008
- Anesthesia: a discipline that incorporates clinical pharmacology across the DDRU continuum.. 84:3-6. 2008
- Inhaled anesthesia: the original closed-loop drug administration paradigm.. 84:15-18. 2008
- Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes.. 84:83-89. 2008
- Processed EEG (bispectral index) is not appropriate for characterizing opioid sedation.. 83:667-668. 2008
- Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.. 83:160-166. 2008
- The importance of including swine and poultry workers in influenza vaccination programs.. 82:638-641. 2007
- Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance.. 82:601-605. 2007
- Should the patent system for new medicines be abolished?. 82:488-490. 2007
- "Personalized medicine: elusive dream or imminent reality?": A commentary.. 81:801-805. 2007
- Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests.. 78:559-581. 2005
- American Society for Clinical Pharmacology and Therapeutics position statement on dietary supplement safety and regulation.. 77:113-122. 2005
- Regulating manufacturer-affiliated communication in the information age.. 65:593-597. 1999
- Bidirectional interaction of valproate and lamotrigine in healthy subjects.. 60:145-156. 1996
- Pharmacokinetics and pharmacodynamics of a new cardiotonic vasodilator agent, 349U85, in normal subjects.. 55:55-63. 1994
- Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers.. 54:670-679. 1993
- Differential response of beta-adrenergic receptor-mediated heart rate and aortic blood flow acceleration to timolol.. 51:296-301. 1992
- Pharmacodynamics of propranolol on left ventricular function: assessment by Doppler echocardiography.. 48:431-438. 1990
- Relationship between alpha 1-acid glycoprotein and lidocaine disposition in myocardial infarction.. 30:154-157. 1981
- Clonidine-chlorthalidone combination once and twice daily in essential hypertension.. 28:581-586. 1980
- Laboratory and clinical studies of penicillin X-1497.. 2:70-79. 1961